Professor Umberto Dalessandro


Director of the MRC Unit The Gambia


MRC Unit The Gambia


Prof. Umberto D'Alessandro (MD, MSc, PhD) has a long working experience in Africa, first as a clinician (Benin and Kenya) and later as a clinical epidemiologist (The Gambia). He has been involved in malaria research since 1990 when he carried out the evaluation of the Gambian National programme on insecticide-treated bed nets. He joined the Department of Parasitology at the Institute of Tropical Medicine, Antwerp, Belgium in 1996 where he was, until the end of 2010, was the head of the Epidemiology Unit. There, he developed a research program around three themes: antimalarial treatment, including drug resistance, malaria prevention, and the P. vivax in vitro cycle, implemented in several malaria endemic countries, e.g. Uganda, Burkina Faso, Benin, Vietnam, Peru, etc.

 In 2011, Professor D’Alessandro joined the Medical Research Council Unit The Gambia (MRCG) as theme leader of disease control and elimination. In January 2014, he was appointed director of the MRCG. His research program on malaria at the MRCG is built around questions related to malaria elimination/eradication.


Department of Disease Control
Faculty of Infectious and Tropical Diseases


Malaria Centre
Centre on Climate Change and Planetary Health


Prof D'Alessandro has supervised 24 PhD students. He is currently supervising 3 PhD students. 

Recently completed doctoral students:

  1. Mwesigwa J. Spatial and Temporal Dynamics of Malaria before and after Mass Drug Administration at the Community Level in The Gambia. Faculty of Medical Sciences, June 2020. UA promoter JP Van geertruyden, Co-promoter U. D'Alessandro
  2. Nambozi M. Antimalarial Treatement Safety and Efficacy in Pregnant Women. Faculty of Medical Sciences, December 2019. UA promoter JP Van geertruyden, Co-promoter U. D'Alessandro
  3. Okebe J. Identifying residual foci of malaria infection in a context of decreasing transmission. From control to elimination: reducing residual malaria transmission in The Gambia. Faculty of Medical Sciences, May 2017. UA promoter JP Van geertruyden, Co-promoters U. D'Alessandro.
  4. Tahita M. Case management and control of Malaria in Pregnancy: Case of Burkina Faso. University of Antwerp, Faculty of Medical Sciences, May 2017. UA promoter JP Van geertruyden , Co-promoters U. D'Alessandro; Halidou Tinto.
  5. Opondo K. Roles of biting preference and insecticide resistance in determining malaria transmission heterogeneity in The Gambia. University of Liverpool, June 2016. UL promoter M Donnelly, Co-Promoter U D’Alessandro 
  6. Kajungu D. Data mining methods for pharmacovigilance in Africa. Catholic University of Leuven, December 2015. UCL promoter N Speybroeck, Co-promoter U. D’Alessandro
  7. Oriero CE. Field implementation and evaluation of novel isothermal, nucleic acid -based diagnostic tools for malaria elimination in sub-Saharan Africa. University of Antwerp, Faculty of Medical Sciences, October 2015. UA promoter JP Van geertruyden , Co-promoters U. D'Alessandro; Jan Jacobs; Davis Nwakanma.
  8. Manyando C. Options for Treatment and Control of Malaria in Pregnancy in Zambia.  University of Antwerp, Faculty of Medical Sciences, 2014. UA promoter JP Van geertruyden , ITM promoter U. D'Alessandro.

Currently supervised PhD students: 

Abdullahi Ahmad (Nigeria) - "The importance of asymptomatic malaria carriers in maintaining transmission"

Edgar Dabira (Burkina Faso) - "Towards malaria elimination: Innovative tools and interventions to accelerate interruption of transmission in The Gambia"

Harouna Soumare (Mali) - "P. falciparum infection dynamics and transmission to inform elimination in Upper Rover Region, The Gambia"


I have started my research career with the evaluation of the impact of the Gambian National insecticide-treated bed nets (ITNs) on childhood morbidity and mortality and on malaria in pregnancy. ITNs reduced mortality in children <10 years of age by 25%. It also showed that ITNs could prevent malaria in pregnancy and this resulted in a higher mean birth weight in intervention villages. This is one of the projects on which the recommendation by the World Health Organization of implementing ITNs for the prevention of malaria is based.

I also carried out, about around the same period, one of the first phase 3 malaria vaccine trials in sub-Saharan Africa, namely SPf66. Unfortunately, the vaccine was not efficacious, but the trial provided important information on how to conduct a malaria vaccine trial.

Antimalarial drug resistance and efficacy of new treatments has been for long time a major subject in my research portfolio. I have contributed assessing the magnitude of the resistance to chloroquine and sulfadoxine-pyrimethamine, both in West and Eastern Africa, and investigated how the intensity of malaria transmission influenced the spread of drug resistant parasites. I have also evaluated the safety and efficacy of artemisinin-based combination treatments in Africa and in other continents, including in high risk groups such as children <5 years old and pregnant women.  For the latter, I reported that dihydroartemisinin-piperaquine is the treatment with the highest efficacy and acceptable safety, while artemether-lumefantrine has excellent safety but lower efficacy.

I have worked extensively on malaria in pregnancy and produced data on the burden of infection and efficacy and effectiveness of control interventions. For example, I evaluated several approaches to increase the coverage of intermittent preventive treatment during pregnancy (IPTp), one of them combining IPTp with malaria screening and treatment between IPTp doses.

In the last 10 years, I investigated residual malaria transmission and factors maintaining it; and I have evaluated interventions with the potential of further reducing or interrupting residual malaria transmission. I have characterized malaria transmission across The Gambia and established the likely ‘parasite flow’ by genotyping and modelling, showing that transmission in western Gambia is partly maintained by parasites from eastern Gambia. We carried out several cluster randomized trials to evaluate the safety, efficacy and acceptability of different control interventions. For example, we recently evaluated the impact mass drug administration with ivermectin (endectocidal drug that may reduce vector survival after a blood meal) and dihydroartemisinin‐piperaquine on residual malaria transmission. The intervention decreased significantly malaria prevalence in intervention villages.  

We carried out the first Controlled Human Malaria Infection (CHMI) experiment in The Gambia and showed that individuals with serological evidence of higher malaria exposure were able to better control infection and had higher parasite growth inhibitory activity.

Finally, the MRC Unit The Gambia I am leading is fully involved in the national response to the covid-19 epidemic. Besides providing the diagnostic facilities and managing patients in our clinical services, we have bene doing several covid-19 related projects. We have evaluated a new antigen-based diagnostic test and set up a cohort of covid-19 patients to determine their immune response over 6 months. We are implementing a treatment trial with 2 cohorts, one with mild disease patients and the other with severe disease patients.

Research Area
Child health
Clinical care
Clinical trials
Drug resistance
Maternal health
Perinatal health
Public health
Disease control
Global Health
Neonatal health
Randomised controlled trials
Genetic epidemiology
Molecular epidemiology
Disease and Health Conditions
Cardiovascular disease
Infectious disease
Burkina Faso
The Gambia
Sub-Saharan Africa (developing only)

Selected Publications

Age-modified factors associated with placental malaria in rural Burkina Faso.
Bihoun B; Zango SH; Traoré-Coulibaly M; Valea I; Ravinetto R; Van Geertruyden JP; D'Alessandro U; Tinto H; Robert A
BMC Pregnancy and Childbirth
A Cohort Study on the Duration of Plasmodium falciparum Infections During the Dry Season in The Gambia.
Collins KA; Ceesay S; Drammeh S; Jaiteh FK; Guery MA; Lanke K; Grignard L; Stone W; Conway DJ; D'Alessandro U
The Journal of infectious diseases
The PRECISE-DYAD protocol: linking maternal and infant health trajectories in sub-Saharan Africa
Craik R; Volvert M-L; Koech A; Jah H; Pickerill K; Abubakar A; D'Alessandro U; Barratt B; Blencowe H; Bone JN
Wellcome Open Research
Ivermectin for malaria control in mass drug administration programmes - Authors' reply.
Dabira ED; D'Alessandro U
The Lancet. Infectious diseases
Plasmodium falciparum merozoite invasion ligands, linked antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia.
Mbye H; Mane K; Diop MF; Demba MA; Bojang F; Mohammed NI; Jeffries D; Quashie NB; D'Alessandro U; Amambua-Ngwa A
Journal of Antimicrobial Chemotherapy
Skin microbiome alters attractiveness to Anopheles mosquitoes.
Showering A; Martinez J; Benavente ED; Gezan SA; Jones RT; Oke C; Tytheridge S; Pretorius E; Scott D; Allen RL
BMC microbiology
Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data.
Stepniewska K; Allen EN; Humphreys GS; Poirot E; Craig E; Kennon K; Yilma D; Bousema T; Guerin PJ; White NJ
BMC medicine
Interplay between sickle cell anaemia and Plasmodium falciparum malaria.
Talisuna AO; D'Alessandro U
The Lancet. Child & adolescent health
See more Publications